Abstract Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

The primary outcome rates with apixaban 2.5 mg twice daily and 5 mg once daily were 9.0% and 11.3%, respectively, compared with 15.6% in the enoxaparin group and 26.6% in the warfarin group (p = 0 ...

Eliquis (apixaban) is a brand-name oral tablet that’s prescribed for preventing or treating certain blood clots in adults. The cost of the drug with and without insurance can depend on several ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback. At ...

Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...

Eliquis (apixaban) is an anticoagulant used to lower the chance of stroke in people with atrial fibrillation (AFib), a common type of irregular heartbeat (arrhythmia). Most Medicare prescription ...

Extended anticoagulation using reduced-dose apixaban was found to be noninferior to using full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients who had active cancer ...

On CAT analysis, the apixaban group exhibited a higher rate of TG compared to the rivaroxaban group (66.52nM/min vs. 35.8nM/min, p=0.02). In the apixaban group, a decrease in TEG reaction time (R-time ...

In a prospective study of 1697 apixaban users, hemorrhage occurred at an overall rate of 10.8 per 100 person-years. While age was not associated with hemorrhage — rates were 10.9 and 10.1 per 100 ...

Contents Monthly recap of health product safety information Gadolinium-based contrast agents JAMP-pregabalin 50 mg Seasonique (levonorgestrel and ethinyl estradiol tablets, and ethinyl estradiol ...

Direct oral anticoagulants (DOACs)—dabigatran, rivaroxaban, apixaban and edoxaban—are changing the landscape of clinical practice for patients requiring short and long-term anticoagulation. We report ...